2015_03_17_MED_bbva

The BBVA Foundation has awarded 150,000 euros to a study on cancer immunotherapy, led by Dr. Ignacio Melero Bermejo, Ph. Clínica Universidad de Navarra study on cancer immunotherapy, directed by Dr. Ignacio Melero Bermejo, researcher of the CIMA (research center Médica Aplicada) and Clínica Universidad de Navarra and main author of the study. This is one of the six biomedicine projects chosen from among nearly 600 applications submitted to the first edition of the BBVA Foundation Grants for research projects in Socioeconomics, Ecology and Conservation Biology, Humanities digital, and Biomedicine.

"The project, which will be developed over the next three years, focuses on a phase II clinical essay that will apply immunotherapy with dendritic cells and hiltonol in patients with advanced solid tumors," describes Dr. Melero. The goal of the research is "to evaluate the antitumor efficacy of this combination of immunotherapies in a essay with patients with advanced tumors. The hypothesis is that there is a synergistic effect, as has been observed in animal models in our laboratory", indicates the specialist.

The study is part of one of the strategic lines of research translational (from programs of study preclinical to clinical trials) on cancer immunotherapy developed by group of researchers from the Clinic and CIMA: Cellular immunotherapy of solid tumors, including combined strategies using dendritic cells, T lymphocytes and NK cells.